🔎 Trials Near Me

Beranda › Kanker Paru Non-Sel Kecil › Texas › Austin

Uji klinis Kanker Paru Non-Sel Kecil di Austin, TX

30 studi untuk Kanker Paru Non-Sel Kecil mencari peserta di lokasi sekitar Austin (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Menerima pesertaFase 1/2
  • New Experimental Therapeutics - NEXT Oncology, Austin
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT04585750

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

Menerima pesertaFase 1
  • NEXT Austin, Austin
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06270706

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Menerima pesertaFase 1
  • Exelixis Clinical Site #46, Austin
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT05176483

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

Menerima pesertaFase 3
  • Texas Oncology-Austin Central, Austin
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT07361497

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Menerima pesertaFase 3
  • Texas Oncology - South Austin, Austin
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT06881784

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

Menerima pesertaFase 3
  • Texas Oncology- Central South., Austin
  • Texas Oncology Central South, Austin
  • Texas Oncology- Central South., Austin
  • dan 1 lainnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07144280

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Menerima pesertaFase 3
  • Texas Oncology - Central/South Texas, Austin
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07222566

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

Menerima pesertaFase 1/2
  • Next Oncology - Austin, Austin
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07488676

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Menerima pesertaFase 3
  • Clinical Study Site, Austin
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Sep 2026 · NCT06767514

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Menerima pesertaFase 1/2
  • Texas Oncology (Balcones) - SCRI, Austin
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Sep 2026 · NCT05267626

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Menerima pesertaFase 2/3
  • Local Institution - 007-892-B, Austin
  • Local Institution - 007-892-A, Austin
  • USOR - Texas Oncology - Dallas Fort Worth (DFW) - South Austin, Austin
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT04613596

A Phase 1/1b Study of IAM1363 in HER2 Cancers

Menerima pesertaFase 1
  • NEXT Oncology - Austin, Austin
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT06253871

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Menerima pesertaFase 3
  • USO - Texas Oncology, Austin
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT06119581

A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

Menerima pesertaFase 1
  • NEXT Oncology Texas, Austin
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT07361562

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

Menerima pesertaFase 3
  • Research Site, Austin
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT07291037

Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

Menerima pesertaFase 1
  • NEXT Oncology - Austin, Austin
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Agu 2026 · NCT07444814

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Menerima pesertaFase 1/2
  • Texas Oncology - Central / South Texas, Austin
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Agu 2026 · NCT05579366

Study of XB010 in Subjects With Solid Tumors

Menerima pesertaFase 1
  • NEXT Austin, Austin
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Jun 2026 · NCT06545331

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

Menerima pesertaFase 1
  • NEXT Texas LLC - Austin, Austin
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Jun 2026 · NCT07503808

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

Menerima pesertaFase 1
  • NEXT Texas LLC - Austin, Austin
Usia 18 hingga 99 · Semua jenis kelamin · Diperbarui 16 Jun 2026 · NCT07540572

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

Menerima pesertaFase 2
  • Texas Oncology - Austin Central, Austin
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Jun 2026 · NCT06463665

Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

Menerima pesertaFase 3
  • Sarah Cannon Research Institute (SCRI) - Texas Oncology-Central South, Austin
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 19 Mei 2026 · NCT07154706

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Menerima pesertaFase 1/2
  • University of Texas at Austin, Austin
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Mei 2026 · NCT05379985

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

Menerima pesertaFase 1
  • NEXT Oncology, Austin, TX 78758
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Apr 2026 · NCT06451497

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

Menerima pesertaFase 1
  • Dren Investigational Site, Austin
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 7 Jan 2026 · NCT06999187

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

Menerima pesertaFase 1/2
  • Research Site 135, Austin
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Nov 2025 · NCT05914116

A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer

Menerima pesertaFase 2
  • TxO Central/South, Texas Oncology -Central/South Texas, Austin
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2025 · NCT06868485

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

Menerima pesertaFase 1/2
  • NEXT Austin, Austin
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 7 Jan 2025 · NCT06090266

Uji klinis Kanker Paru Non-Sel Kecil di kota lain

Studi lain di Austin

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.